Search Results

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Resources RESOURCES > SUPPORT FOR THE ENSURING PATHWAYS TO INNOVATIVE CURES (EPIC) ACT > SIGN-ON LETTER TO CONGRESS RE. CMS NCD WITH CED FOR ALZHEIMER'S TREATMENTS Sign on Letter to Congress re: CMS NCD with CED for Alzheimer's treatments The Partnership to Fight Chronic Disease (PFCD) and several of our partners are working together to raise awareness and call for reconsideration of the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination with Coverage with Evidence Development for an entire class of new, FDA-approved treatments for Alzheimer's Disease. This decision has ripple effects beyond just the Alzheimer's community and sets a dangerous precedent for other people living with chronic conditions. We have drafted a SIGN ON LETTER and welcome organizations to join us in calling on Congress to take action in requesting CMS to reverse this decision that compromises patients, families, caregivers and providers managing this progressive, debilitating disease. Name Organization Title Email Address Submit Thank you. Your message has been sent.

The Partnership to Fight Chronic Disease (PFCD) is an internationally-recognized organization of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs: chronic disease Resources MOST FAVORED NATION SUPPORT FOR THE ENSURING PATHWAYS TO INNOVATIVE CURES (EPIC) ACT FEWER TREATMENTS RESULTING FROM IRA PRICE CONTROLS PRESCRIPTION DRUG AFFORDABILITY BOARDS WILL LIMIT ACCESS TO LIFESAVING MEDICINES DEFINING "UNMET MEDICAL NEED" OBESITY U.S. BURDEN OF NEURO-DEGENERATIVE DISEASE NATIONAL PANDEMIC PREPAREDNESS STRATEGY STATEMENT OF PRINCIPLES QUANTIFYING IMPACT OF ACCELERATED APPROVAL DRUGS ON MEDICAID SPENDING MIGRAINE ARTHRITIS ALZHEIMER'S HEART DISEASE

Partnership to Fight Infectious Disease is a group of patients, providers, community organizations, business and labor groups, and health policy experts working to advance awareness and action on antimicrobial resistance. PFCD in the States As lawmakers continuously review changes to our health care system, it is incumbent upon leaders on both sides of the aisle to acknowledge the single largest driver of health care spending — chronic disease — and present a concrete plan for addressing this human and economic threat. Ninety cents of every health care dollar spent is spent on treating people with chronic disease. Chronic diseases are the leading causes of death and disability. One in two Americans lives with at least one chronic condition and almost three in four older Americans have one or more than one chronic condition. The good news is that most chronic diseases are preventable or manageable. With a health care system that better detects, treats, and manages chronic disease, we can change our nation’s health care story, improve the lives of millions of Americans, and strengthen our economy by tackling chronic disease. Join us in the #Fight4Health and demand leadership on the issue from all our policymakers. PFCD worked with GlobalData on a microsimulation analysis to assess chronic disease trends in the U.S. and across the states. The fact sheet data highlights averages of annual outcomes from 2025–2039.For more information about the study and methodology, read the Burden of Chronic Disease in US Children and Adults: Model Technical Document . U.S. Chronic Disease Fact Sheet U.S. Childhood Health Fact Sheet U.S. Health Equity Fact Sheet

May 20, 2026 (Washington, D.C.) The Partnership to Fight Chronic Disease (PFCD) released the following statement in advance of this week’s anticipated Senate vote-a-rama on the reconciliation bill: “The Partnership to Fight Chronic Disease urges Congress to carefully consider the unintended consequences that foreign drug pricing policies could have for Americans living with one or more chronic conditions. “Patients living with cancer, Alzheimer’s disease, autoimmune disorders, cardiovascular disease, diabetes, and rare diseases depend on timely access to innovative medicines and individualized treatment options. Policies that tie U.S. drug prices to foreign government-controlled systems risk importing the same delays, coverage restrictions, and rationing practices that limit patient access in other countries. “Many of the countries used as reference points for Most Favored Nation (MFN) pricing proposals routinely restrict access to newer therapies and rely on cost-effectiveness measures, including the use of the quality-adjusted life year, or QALY, that can disadvantage older adults, people with disabilities, and patients with complex chronic conditions. The result is reduced treatment choices and delayed access to therapies that can improve or extend lives. “PFCD is also deeply concerned about the long-term impact these policies could have on medical innovation. Breakthroughs in cancer, cardiovascular disease, obesity, diabetes, rare diseases, and other chronic conditions have transformed patient outcomes and created new hope for millions of families. Importing foreign price controls would weaken the research and development ecosystem that drives future cures and treatment advances. “Americans living with chronic disease deserve policies that improve affordability and strengthen access without sacrificing innovation, physician and patient choice, or future medical progress. Congress should reject foreign pricing policies that risk undermining patient care and instead pursue solutions that address the true drivers of health care costs while preserving access to life-saving treatments.” ###

April 17, 2026 (Washington, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement today in response to recent analyses related to Alzheimer’s disease. “The recent review of anti-amyloid Alzheimer’s therapies highlights the complexity of measuring progress against a devastating disease, but its conclusions should be viewed with important context. By combining older, unsuccessful therapies with newer treatments that have demonstrated the ability to slow cognitive decline, the analysis risks misrepresenting meaningful advances and diminishing what these medicines can offer patients and families today. “For those living with Alzheimer’s and related dementias, even modest slowing of disease progression, such as the reductions in decline observed in recent trials, can translate into more time with loved ones, greater independence, and a critical window for future breakthroughs. Dismissing these gains because they are not cures overlooks what matters most to patients and caregivers. “At a time when the burden of Alzheimer’s continues to grow, the answer is not to step back from innovation, but to build on it, advancing a range of scientific approaches, improving how we measure meaningful outcomes, and ensuring patients have access to emerging therapies. The Partnership to Fight Chronic Disease remains committed to supporting continued research, thoughtful evaluation of evidence, and policies that accelerate progress for the millions of Americans affected by this disease.” ###

Patients lose access to lifesaving therapies when governments impose drug price controls, and the consequences are measured in delayed treatment, depleted research pipelines and lives cut short, according to a new research analysis from the Information Technology and Innovation Foundation (ITIF). ITIF examined how European drug pricing policies drove the continent's fall from global biopharmaceutical leadership. While compiling and assessing existing research on the patient impact, the independent think tank called Europe a "cautionary tale" for the U.S., particularly as the Trump administration continues to champion the expansion of price controls through “Most Favored Nation” (MFN) drug pricing policies. Patient wait times for treatment availability, as measured from regulatory approval to payer coverage, were slower in 25 of the 27 EU nations compared to the U.S. from 2014 to 2022, according to IQVIA. The Galen Institute found that, of 290 new medicines introduced globally between 2011 and 2018, 89% were available in the U.S. compared with only 62% in Germany, 48% in France and Switzerland, and 40% in Ireland. The data were starker for oncology medicines: 96% were available to American patients compared with 73% in Germany, 66% in France, 62% in Switzerland and 51% in Ireland. The report also traced the erosion of the pipelines that deliver patients new therapies. Between 1960 and 1965, European firms produced 65% of all new medicines worldwide. By 2004, that share collapsed to 18% while the U.S. share climbed to 62%. ITIF cited research by University of Southern California health economist Darius Lakdawalla and his colleagues, who found that lowering U.S. drug prices to European levels would reduce life expectancy for adults ages 55 to 59 by roughly two-tenths of a year. That amounts to more than four million life-years lost across that age group alone. For the more than 194 million Americans living with multiple chronic conditions, the analysis of Europe's decline hits close to home. These patients depend on a steady flow of new therapies to manage illness, preserve quality of life and survive. As a recent Partnership to Fight Chronic Disease study explored, chronic conditions are the primary driver  of rising health care spending across Medicare, Medicaid and private insurance, and obesity is a primary culprit. Adding longer wait times for new treatments to an already strained U.S. health care system would delay care, worsen patient outcomes and drive costs higher. The risk is too great. Ultimately, ITIF's analysis is a patient story. Europe's experience shows what happens when governments suppress the returns that fuel innovation. Americans with chronic disease cannot afford for history to be repeated. The full report from ITIF can be found HERE .